Search results for "Vaccines"

showing 10 items of 554 documents

The F4/AS01B HIV-1 Vaccine Candidate Is Safe and Immunogenic, But Does Not Show Viral Efficacy in Antiretroviral Therapy-Naive, HIV-1-Infected Adults…

2016

Supplemental Digital Content is available in the text

0301 basic medicinemyalgiaAdultCD4-Positive T-LymphocytesMalemedicine.medical_specialty4850AdolescentMedizinHIV InfectionsVacunesPlaceboAntibodies Virallaw.invention03 medical and health sciencesYoung Adult0302 clinical medicineRandomized controlled triallawInternal medicineVIH (Virus)medicineHumansSingle-Blind Method030212 general & internal medicineYoung adultAdverse effectAIDS VaccinesVaccinesHIV (Viruses)business.industryClinical Trial/Experimental StudyGeneral MedicineConfidence intervalCD4 Lymphocyte CountClinical trial030104 developmental biologyAnti-Retroviral AgentsImmunologyAntibody FormationComputingMethodologies_DOCUMENTANDTEXTPROCESSINGHIV-1Femalemedicine.symptombusinessViral loadResearch Article
researchProduct

Preproinsulin designer antigens excluded from endoplasmic reticulum suppressed diabetes development in nod mice by dna vaccination

2019

DNA vaccines against autoimmune type 1 diabetes (T1D) contain a nonpredictable risk to induce autoreactive T cell responses rather than a protective immunity. Little is known if (and how) antigen expression and processing requirements favor the induction of autoreactive or protective immune responses by DNA immunization. Here, we analyzed whether structural properties of preproinsulin (ppins) variants and/or subcellular targeting of ppins designer antigens influence the priming of effector CD8+ T cell responses by DNA immunization. Primarily, we used H-2b RIP-B7.1 tg mice, expressing the co-stimulator molecule B7.1 in beta cells, to identify antigens that induce or fail to induce autoreacti…

0301 basic medicinepreproinsulin/proinsulin antigensPreproinsulinlcsh:QH426-470type 1 diabetesMouse ModelsBiologyMajor histocompatibility complexArticleDNA vaccinationDNA vaccines03 medical and health sciences0302 clinical medicineImmune systemAntigenImmunityGeneticsmouse models:Science::Medicine [DRNTU]lcsh:QH573-671Molecular BiologyNOD micelcsh:Cytologylcsh:Geneticsendoplasmic reticulum030104 developmental biology030220 oncology & carcinogenesisImmunologybiology.proteinType 1 DiabetesMolecular MedicineCD8
researchProduct

Towards a European strategy to address the COVID-19 pandemic

2021

2019-20 coronavirus outbreakCOVID-19 VaccinesCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Physical DistancingMass Vaccination03 medical and health sciences0302 clinical medicinePolitical scienceCorrespondencePandemicHumans030212 general & internal medicinePandemicsHealth policy030304 developmental biology0303 health sciencesSARS-CoV-2Health PolicyIncidenceIncidence (epidemiology)COVID-19General MedicineVirology3. Good healthEuropeMass vaccinationHuman medicineThe Lancet
researchProduct

GRAd-COV2, a gorilla adenovirus-based candidate vaccine against COVID-19, is safe and immunogenic in younger and older adults

2022

International audience; Safe and effective vaccines against coronavirus disease 2019 (COVID-19) are essential for ending the ongoing pandemic. Although impressive progress has been made with several COVID-19 vaccines already approved, it is clear that those developed so far cannot meet the global vaccine demand alone. We describe a COVID-19 vaccine based on a replication-defective gorilla adenovirus expressing the stabilized prefusion severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein named GRAd-COV2. We assessed the safety and immunogenicity of a single-dose regimen of this vaccine in healthy younger and older adults to select the appropriate dose for each age group…

2019-20 coronavirus outbreakCOVID-19 VaccinesSettore BIO/06Coronavirus disease 2019 (COVID-19)COVID-19 VaccineSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)GorillaAdenoviridaeAdenovirus Vaccinesbiology.animalPandemicAnimalsHumansMedicineMESH: COVID-19MESH: AnimalsMESH: SARS-CoV-2AgedMESH: Adenovirus VaccinesMESH: AgedGorilla gorilla[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyMESH: HumansbiologyAnimalSARS-CoV-2business.industryMESH: Gorilla gorillaCOVID-19MESH: AdenoviridaeGeneral MedicineVirologyAdenovirus VaccineMESH: COVID-19 Vaccinesbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyHuman
researchProduct

Attitudes of Healthcare Personnel towards Vaccinations before and during the COVID-19 Pandemic

2021

Vaccines constitute highly effective tools for controlling and eliminating vaccine-preventable diseases (VPDs) and are assessed to avert between two to three million deaths per year globally. Healthcare personnel (HCP) constitute a priority group for several vaccinations. However, studies indicate significant rates of vaccine hesitancy among them and, therefore, of acceptance of vaccination recommendations. This cross-sectional study was conducted in a university hospital in Southern Italy to assess the knowledge and attitudes of HCP about VPDs before and during the COVID-19 pandemic, estimate their intention to get vaccinated against COVID-19, and search for determinants that may influence…

2019-20 coronavirus outbreakHealth Knowledge Attitudes PracticeknowledgeCOVID-19 VaccinesCoronavirus disease 2019 (COVID-19)Cross-sectional studyOccupational riskHealth Toxicology and MutagenesisCOVID-19 Vaccinelcsh:MedicineArticle03 medical and health sciences0302 clinical medicineSurveys and QuestionnairesEnvironmental healthHealth carePandemicoccupational riskHumansMedicineSurveys and Questionnaire030212 general & internal medicinePandemicsCross-Sectional Studie0303 health sciencesattitudes030306 microbiologybusiness.industrySARS-CoV-2lcsh:RPublic Health Environmental and Occupational HealthCOVID-19University hospitalvaccinationVaccinationCross-Sectional StudiesAttitudeItalyPandemics.vaccine hesitancybusinessHumanhealthcare personnelInternational Journal of Environmental Research and Public Health
researchProduct

Racing for a SARS‐CoV‐2 vaccine

2021

Interview with EMBO Members Özlem Türeci and Uğur Şahin, BioNTech, conducted by science journalist Kai Kupferschmidt.

2019-20 coronavirus outbreakMedicine (General)COVID-19 VaccinesCoronavirus disease 2019 (COVID-19)SARS-CoV-2business.industrySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)ImmunologyCOVID-19QH426-470VirologyR5-920GeneticsHumansMolecular MedicineMedicineInterviewbusinessEMBO Molecular Medicine
researchProduct

Acceptance of SARS-CoV-2 Vaccination Among a Cohort of IBD Patients From Southern Italy: A Cross-Sectional Survey

2021

2019-20 coronavirus outbreakmedicine.medical_specialtyCOVID-19 VaccinesCoronavirus disease 2019 (COVID-19)Cross-sectional studySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Directive CounselingInternal medicineHumansImmunology and AllergyMedicineFamilyPhysician's RoleLetter to the EditorAcademicSubjects/MED00260Ibdjnl/1SARS-CoV-2business.industryGastroenterologistsVaccinationAge FactorsGastroenterologyCOVID-19Inflammatory Bowel DiseasesPatient Acceptance of Health CareInflammatory Bowel DiseasesVaccinationItalyInfluenza VaccinesCohortbusinessAttitude to HealthInflammatory Bowel Diseases
researchProduct

Urology practice during the COVID-19 vaccination campaign

2021

Introduction: The current scenario of the COVID-19 pandemic is significantly different from that of the first, emergency phase. Several countries in the world are experiencing a second, or even a third, wave of contagion, while awaiting the effects of mass vaccination campaigns. The aim of this report was to provide an update of previously released recommendations on prioritization and restructuring of urological activities. Methods: A large group of Italian urologists directly involved in the reorganization of their urological wards during the first and second phase of the pandemic agreed on a set of updated recommendations for current urology practice. Results: The updated recommendations…

2019-20 coronavirus outbreakmedicine.medical_specialtyCOVID-19 VaccinesCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronaviru030232 urology & nephrologycoronavirusmedicine.disease_causesurgery03 medical and health sciences0302 clinical medicinevaccinePandemicmedicineHumansOriginal Research Articlecoronavirus; COVID-19; pandemic; vaccine; urology; clinical practice guidelines; surgery; endourologyurologyPandemicsCoronavirusbusiness.industryImmunization ProgramsSARS-CoV-2pandemicendourologyCOVID-19General MedicineVirologySmart communication (SC173–SC181) Urinary stones: timing and assessmentVaccination030220 oncology & carcinogenesisEmergency medicineUrologic Surgical ProceduresCOVID-19; Coronavirus; clinical practice guidelines; endourology; pandemic; surgery; urology; vaccinebusinessclinical practice guidelinesclinical practice guideline
researchProduct

Therapeutic Vaccination of Hematopoietic Cell Transplantation Recipients Improves Protective CD8 T-Cell Immunotherapy of Cytomegalovirus Infection

2021

Reactivation of latent cytomegalovirus (CMV) endangers the therapeutic success of hematopoietic cell transplantation (HCT) in tumor patients due to cytopathogenic virus spread that leads to organ manifestations of CMV disease, to interstitial pneumonia in particular. In cases of virus variants that are refractory to standard antiviral pharmacotherapy, immunotherapy by adoptive cell transfer (ACT) of virus-specific CD8+ T cells is the last resort to bridge the “protection gap” between hematoablative conditioning for HCT and endogenous reconstitution of antiviral immunity. We have used the well-established mouse model of CD8+ T-cell immunotherapy by ACT in a setting of experimental HCT and mu…

Adoptive cell transfermedicine.medical_treatmentImmunologyCytomegalovirusCD8-Positive T-LymphocytesLymphocyte ActivationCD8+ T cellsVirusCytomegalovirus VaccinesImmunocompromised HostAntigenvaccineMHC class ImedicineImmunology and AllergyCytotoxic T cellAnimalsCells Culturedadoptive cell transferCell ProliferationOriginal ResearchHCMV dense bodiesbiologybusiness.industryVaccinationHematopoietic Stem Cell TransplantationImmunotherapyRC581-607VirologyAdoptive TransferTransplantationMice Inbred C57BLantiviral protectionT cell primingDisease Models AnimalT cell receptor transgenic cellsCytomegalovirus InfectionsHost-Pathogen Interactionsbiology.proteinFemaleVirus Activationsubviral particlesImmunologic diseases. AllergybusinessCD8Frontiers in Immunology
researchProduct

Interleukin-7 or Interleukin-15 Enhances Survival ofMycobacterium tuberculosis-Infected Mice

2000

ABSTRACTBoth antigen-presenting cells and immune effector cells are required to effectively eradicate or containMycobacterium tuberculosis-infected cells. A variety of cytokines are involved to ensure productive “cross talk” between macrophages and T lymphocytes. For instance, infection of macrophages with mycobacteria leads to effective interleukin-7 (IL-7) and IL-15 secretion, and both cytokines are able to maintain strong cellular immune responses of α/β and γ/δ T cells. Here we show that either cytokine is able to enhance survival ofM. tuberculosis-infected BALB/c mice significantly compared to application of IL-2, IL-4, or phosphate-buffered saline (as a control). Enhanced survival cou…

Adoptive cell transfermedicine.medical_treatmentImmunologySpleenBiologyMicrobiologyMiceImmune systemmedicineAnimalsTuberculosisInterleukin-15Mice Inbred BALB CInterleukin-7InterleukinMycobacterium tuberculosisT lymphocyteAdoptive TransferDisease Models AnimalInfectious Diseasesmedicine.anatomical_structureCytokineInterleukin 15Microbial Immunity and VaccinesImmunologyCytokinesFemaleParasitologyTumor necrosis factor alphaSpleenInfection and Immunity
researchProduct